



liberty health sciences

## **Liberty Health Sciences To Open Five New Dispensaries, Bringing Total Number Of Florida Locations To 12 By Year End**

- *Miami and Dania Beach to open by end of November*
- *Hollywood, Bonita Springs and Orange Park, to open by end of December*

**Toronto, ON – November 21, 2018** — Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: [LHSIF](http://LHSIF)) [www.libertyhealthsciences.com](http://www.libertyhealthsciences.com) (“Liberty” or the “Company”), a provider of high quality cannabis, announced today that it plans to open two new dispensaries in Miami and Dania Beach by the end of November and three more in Hollywood, Bonita Springs and Orange Park by the end of this December. Each of the dispensaries will feature free 24-hour delivery service throughout their service area.

The new dispensaries are located at 6827 Bird Road, **Miami, FL.**; 1103 South Federal Highway, **Dania Beach, FL.**; 2119A Hollywood Blvd., **Hollywood, FL.**; 24611 Production Circle, **Bonita Springs, FL.**; 1907-3 Wells Road, **Orange Park, FL.** The dispensaries are open Monday through Friday, 10 a.m. to 7p.m., Saturday, 10 a.m. to 5 p.m., and Sunday 12 p.m. to 5 p.m. Currently, Liberty operates seven dispensaries and six delivery hubs throughout Florida. By the end of the calendar year, Liberty plans to have 12 dispensaries open throughout the state, subject to the receipt of Florida Department of Health approvals.

Liberty’s dispensaries offer pharmaceutical-grade cannabis products along with educational tools and compassionate one-on-one consultations geared towards informing customers on medical cannabis use. Early next year Liberty expects to boost its total cultivation space to 225,000 square feet at its Liberty 360° Innovation Campus in Gainesville, Fl. The Company also plans to add more than 25,000 square feet to house processing and packaging, a patient call center, and all support services. The Company employs more than 150 people in the state.

“Liberty is now expanding exponentially and has become a formidable player in the Florida market,” said George Scorsis, CEO of Liberty Health Sciences. “As we expand our footprint, we remain laser focused on the customer experience. We always place the customer at the forefront of everything we do – from growing and cultivating cannabis, to processing, extraction and developing branded cannabis-related products – the customer always comes first. We control our entire supply chain, from seed to sale and beyond.”

### **About Liberty Health Sciences Inc.**

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers’ well-being at the forefront of what we do. For more information, please visit: [www.libertyhealthsciences.com](http://www.libertyhealthsciences.com).

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:** This press release contains certain forward-looking statements within the meaning of applicable securities

laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

**Media Contacts:**

Dwain Schenck

203-223-5230

[dwain@schenckstrategies.com](mailto:dwain@schenckstrategies.com)

Stephanie Kubacki

Vice-President, Marketing

415-830-7337

[skubacki@libertyhealthsciences.com](mailto:skubacki@libertyhealthsciences.com)

#